Citatuzumab bogatox is a monoclonal antibody that targets the protein known as the epithelial cell adhesion molecule (EpCAM), which is often overexpressed in various epithelial cancers. This therapeutic agent is primarily investigated for its potential use in treating solid tumors, particularly in patients with advanced or metastatic cancers. As a monoclonal antibody, citatuzumab bogatox works by binding to EpCAM on the surface of cancer cells, which can lead to immune-mediated destruction of these cells. The CAS number 945228-49-9 uniquely identifies this compound in chemical databases, facilitating research and regulatory processes. The development of citatuzumab bogatox reflects the growing trend in cancer therapy towards targeted treatments that aim to minimize damage to healthy tissues while maximizing the therapeutic effect on cancer cells. Its efficacy and safety profile are subjects of ongoing clinical trials, which are essential for determining its potential role in oncology.

Citatuzumab bogatox

945228-49-9: Citatuzumab bogatox is a monoclonal antibody that targets the protein known as the epithelial cell adhesion molecule (EpCAM), which is often overexpressed in various epithelial cancers. This therapeutic agent is primarily investigated for its potential use in treating solid tumors, particularly in patients with advanced or metastatic cancers. As a monoclonal antibody, citatuzumab bogatox works by binding to EpCAM on the surface of cancer cells, which can lead to immune-mediated destruction of these cells. The CAS number 945228-49-9 uniquely identifies this compound in chemical databases, facilitating research and regulatory processes. The development of citatuzumab bogatox reflects the growing trend in cancer therapy towards targeted treatments that aim to minimize damage to healthy tissues while maximizing the therapeutic effect on cancer cells. Its efficacy and safety profile are subjects of ongoing clinical trials, which are essential for determining its potential role in oncology.

Citatuzumab bogatox is a recombinant immunotoxin targeting EpCAM with the toxin bouganin, inducing apoptosis in EpCAM-positive tumors.

Antibody-drug conjugate (ADC) Cituximab bogatox is a therapeutic agent comprising a Fab fragment of a humanized antibody directed against EpCAM and a modified cytotoxin bouganin.

CAS 945228-49-9

Citatuzumab bogatox

Citatuzumab bogatox

Ref: TM-T76799

Citatuzumab

Ref: 3D-CLA1182

Citatuzumab Bogatox

Ref: 3D-CLA1182A